Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;19(5):251-263.

Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease

Virginia Solitano  1   2   3 , Christopher Ma  2   4   5 , Jurij Hanžel  2   6 , Remo Panaccione  4 , Brian G Feagan  1   2   7 , Vipul Jairath  1   2   7
Affiliations

Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease

Virginia Solitano et al. Gastroenterol Hepatol (N Y). 2023 May.

Abstract

The use of combination therapy with a biologic agent and immunosuppressant has well-established efficacy and safety and is common practice in the management of inflammatory bowel disease (IBD). Current research has shifted focus toward the use of advanced combination treatment (ACT). This term was coined to describe combination therapy using 2 or more advanced treatments (biologic agents and/or oral small molecule drugs) with the aim of achieving optimal disease control in selected patients. An ACT approach may be particularly beneficial in patients with documented medically refractory IBD and in patients with a poor prognosis, extraintestinal manifestations, or concomitant immune-mediated inflammatory diseases. To date, the body of evidence for ACT strategies in IBD is largely comprised of uncontrolled retrospective case series and cohort studies in highly refractory patients. Recently, results from the VEGA trial have suggested that combination induction therapy with guselkumab and golimumab was more effective in ulcerative colitis than either agent alone. However, questions remain about issues such as related costs, ACT duration, and optimal combinations to adopt. Future randomized controlled trials are likely to evaluate rationally selected combinations of agents. This article summarizes the available literature on ACT, including comparisons with traditional combination therapy and the rheumatology field, and discusses practical recommendations, profiles of IBD patients who should be considered for combination approaches in clinical practice, and remaining knowledge gaps.

Keywords: Advanced combination treatment; Crohn’s disease; dual biologic therapy; dual targeted therapy; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
From traditional to advanced combination treatment: weighing benefits and drawbacks. EIM, extraintestinal manifestation; IBD, inflammatory bowel disease; IMID, immune-mediated inflammatory disease.
Figure 2.
Figure 2.
Potential advanced combination treatment trial designs. A represents the first drug and B represents the second drug in the combination.
See this image and copyright information in PMC

References

    1. Hanauer SB, Feagan BG, Lichtenstein GR et al. ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. - PubMed
    1. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65. - PubMed
    1. Rosario M, Dirks NL, Gastonguay MR et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188–202. - PMC - PubMed
    1. Feagan BG, Sandborn WJ, Gasink C et al. UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. - PubMed
    1. Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628–639. - PubMed

LinkOut - more resources